/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen.
Immunotherapy drug benefits patients with high-risk local melanomas miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
TG Therapeutics Recaps Schedul - GuruFocus com gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
TG Therapeutics Announces Data Presentations at the globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.